



CORPORATE FACT SHEET

CorMatrix Cardiovascular

CorMatrix Cardiovascular, Inc. is dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial technologies that harness the body's innate ability to repair damaged cardiovascular tissue. Founded in 2001, the privately-held company is based in Atlanta, Ga.

CorMatrix ECM Technology™

CorMatrix ECM Technology is a platform innovation with multiple cardiovascular applications. This naturally occurring extracellular matrix biomaterial supports native tissue repair by providing an interim bioscaffold, enabling a patients' own cells to repopulate and repair damaged tissues.

The use of the material in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. Since 1999, an estimated 500,000 patients worldwide have received an extracellular matrix implant.

CorMatrix holds an exclusive worldwide license from Purdue University to research, develop, manufacture and market naturally occurring extracellular matrix products for cardiovascular applications.

CorMatrix Cardiovascular Products

CorMatrix ECM Technology enables surgeons to restore the natural anatomy of the body.

The company has obtained U.S. FDA clearance and European approval to market CorMatrix ECM for Pericardial Closure for the reconstruction and repair of the pericardium during cardiac surgery.

CorMatrix also has U.S. FDA clearance for CorMatrix ECM for Cardiac Tissue Repair for suture-line reinforcing, buttressing for soft tissue reapproximation, repair of cannulation sites and bleeding sites, and as an intracardiac patch for tissue repair of structural problems such as septal defects.

CorMatrix ECM has been used at more than 300 hospitals across the U.S. and has been implanted in nearly 20,000 cardiac procedures since its launch in 2006.

###